Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 2Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Rituximab 23Lenalidomide 11Cyclophosphamide 10zanubrutinib 9Bendamustine Hydrochloride 8venetoclax 6ibrutinib 6fludarabine 6parsaclisib 5idelalisib 5ublituximab 4obinutuzumab 4aflibercept 4Prednisone 4pirtobrutinib 3Vincristine 3ME-401 3Doxorubicin 3umbralisib 2tazemetostat 2marizomib 2epratuzumab 2Radioimmunodetection 2voruciclib 1veltuzumab 1varlilumab 1tislelizumab 1tetulomab tetraxetan lu-177 1tafasitamab 1repaglinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell, Marginal Zone × cirmtuzumab × Clear all
NCT03088878 2025-02-12

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Oncternal Therapeutics, Inc

Phase 1/2 Completed
95 enrolled 25 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡